A woman in her early thirties suffered irregular menstruation and two years of unsuccessful conception. She consulted multiple gynecology departments, took menstrual-regulating medications, and underwent ovulation monitoring, yet failed to get pregnant. Her doctor frowned and advised: “Go get a cranial MRI scan.”

The MRI results revealed a pituitary adenoma.

Her infertility stemmed not from gynecological disorders, but from a hormone-secreting intracranial tumor. This represents the typical clinical journey of patients with prolactinomas: they travel a long detour through gynecology before identifying the true root cause.

Pituitary adenomas rank among the most common benign intracranial tumors in adults. The pituitary gland acts as the body’s central endocrine hub, synthesizing and releasing all major hormones. Tumor formation disrupts hormonal balance, which in turn disturbs menstruation, fertility, physical appearance and systemic metabolism.

Not all pituitary adenomas require surgical resection. Clear clinical criteria determine whether medication or surgery is the appropriate first-line treatment.

Functional vs Non-Functional Pituitary Adenomas

Pituitary adenomas are split into two core categories based on endocrine secretory activity.

Functional pituitary adenomas autonomously overproduce specific hormones, leading to elevated serum hormone levels and corresponding systemic symptoms. Distinct hormonal abnormalities trigger entirely different clinical manifestations.

Prolactinomas (the most common subtype)

Excess prolactin causes amenorrhea, galactorrhea, menstrual irregularity and anovulation in women — explaining why most patients initially seek gynecological care. Men may also develop prolactinomas, presenting with decreased libido and gynecomastia.

Growth hormone adenomas

Excess growth hormone in adults does not increase height, but induces enlarged hands and feet, thickened lips and prominent cheekbones; middle-aged patients are often misdiagnosed as merely gaining weight. Childhood-onset lesions trigger precocious puberty and abnormally accelerated linear growth.

ACTH-secreting adenomas

Prolonged excess cortisol induced by these tumors causes Cushing’s syndrome, characterized by moon face, buffalo hump, thin extremities with central obesity, skin striae, hypertension and secondary diabetes mellitus.

Non-functional pituitary adenomas produce no excess hormones, and routine blood endocrine tests may return entirely normal results. However, progressive tumor enlargement compresses adjacent structures, with the optic apparatus most vulnerable. The optic chiasm lies directly above the pituitary gland; upward tumor growth compresses the optic nerve, resulting in visual deterioration and visual field constriction (tunnel vision). Surgical resection is indicated for any tumor compressing the optic nerve, regardless of its size.

Size Classification: 1 Centimeter as the Critical Cutoff

Pituitary adenomas are categorized by diameter into microadenomas and macroadenomas, with 1 cm as the dividing line: lesions under 1 cm are microadenomas, while those exceeding 1 cm are macroadenomas.

Microadenomas are primarily managed with pharmacotherapy. Dopamine receptor agonists serve as first-line agents for prolactinomas, which normalize hormone levels and shrink tumor volume. Many patients achieve stable long-term disease control solely with oral medication, avoiding surgery entirely.

Macroadenomas carry greater compressive risk to surrounding anatomical structures. Surgery becomes mandatory if visual impairment develops or medical therapy yields inadequate tumor control. Rapidly expanding macroadenomas that obstruct the ventricular system and trigger hydrocephalus also require urgent surgical intervention.

A surgical emergency known as pituitary apoplexy occurs when intratumoral hemorrhage or ischemic necrosis develops abruptly. Patients present with severe headache, rapid visual loss and even coma, requiring immediate surgical decompression.

Modern Surgical Approach: Minimally Invasive Transnasal Endoscopic Resection

Upon hearing of an intracranial tumor, most patients immediately worry about craniotomy — this concern is largely unfounded for pituitary adenomas.

Over 90% of pituitary tumor operations adopt the transsphenoidal endoscopic approach. Surgeons insert an endoscope through the nasal cavity, traverse the sphenoid sinus, and reach the sellar region to resect the adenoma. The procedure leaves no external facial incisions, eliminates the need for cranial shaving and craniotomy, delivers far less tissue trauma than traditional open cranial surgery, and enables faster postoperative recovery.

Nevertheless, transnasal endoscopic surgery has limitations. Tumor extension into the cavernous sinus — a space housing the internal carotid artery and multiple cranial nerves — drastically elevates operative risks. Giant adenomas invading the frontal or temporal lobes lie beyond the endoscopic reach, necessitating microsurgical craniotomy.

The selection of surgical corridor depends on three key factors: tumor diameter, direction of invasion, and institutional equipment and technical expertise. Experienced surgeons avoid arbitrary recommendations for craniotomy, and will not force transnasal resection for anatomically unfavorable lesions; treatment plans are individualized to each patient’s imaging features.

Surgery Is Not the Endpoint: Lifelong Endocrine Follow-Up Is Indispensable

One long-term mandatory protocol after pituitary adenoma surgery is regular endocrine surveillance.

As the core endocrine regulatory organ, the pituitary gland may sustain functional damage during tumor resection. Serial hormone testing is required to detect and promptly correct hormonal deficiencies. Many patients mistakenly believe surgery alone cures the condition, only to develop untreated hypothyroidism or hypocortisolism that progresses into severe complications.

Patients with residual prolactinoma after surgery must continue medical therapy to suppress further tumor proliferation.

In summary, the clinical management algorithm for pituitary adenomas follows a clear sequence: first assess for hormonal hypersecretion, then evaluate tumor size and invasion pattern, and finally decide between medical management or surgical resection. Do not be alarmed by the term “tumor”, nor delay evaluation with complacency. Consulting the correct specialty and experienced specialists yields far more reliable outcomes than self-guessing one’s condition.